During the past decade, Institut fur Psychosomatik conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 2 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Institut fur Psychosomatik" are "Attention Deficit Hyperactivity Disorder" (1 trials) and "Attention Deficit Hyperactivity Disorder (ADHD)" (1 trials). Many other conditions were trialed in "Institut fur Psychosomatik" in a lesser frequency.

Most popular intervention types in "Institut fur Psychosomatik" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Atomoxetine Hydrochloride" (1 trials), "Extended-release Guanfacine HCl (Intuniv, SPD503)" (1 trials), "Extended-release Guanfacine Hydrochloride" (1 trials) and "Placebo Comparator" (1 trials). Other intervention names were less common.

The vast majority of trials in "Institut fur Psychosomatik" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Institut fur Psychosomatik". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Institut fur Psychosomatik, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Institut fur Psychosomatik, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".